Literature DB >> 33202149

Using Network Pharmacology for Systematic Understanding of Geniposide in Ameliorating Inflammatory Responses in Colitis Through Suppression of NLRP3 Inflammasome in Macrophage by AMPK/Sirt1 Dependent Signaling.

Zhichen Pu1,2, Yanhao Liu1, Chao Li1, Moadi Xu1, Haitang Xie1, Jun Zhao3.   

Abstract

Ulcerative colitis is a chronic and recurrent inflammatory bowel disease mediated by immune response. Geniposide is the main active ingredient extracted from Gardenia jasminoides, which has been suggested to exert excellent efficacy on inflammatory disease. Herein, in this study, we aimed to uncover the systematic understanding of the mechanism and effects of geniposide in ameliorating inflammatory responses in colitis. In brief, the TCMSP server and GEO DataSets were used to analyze the systematic understanding of the mechanism and effects of geniposide in ameliorating inflammatory responses in colitis. Dextran Sulfate Sodium (DSS)-induced acute colitis of mice were administered with 25-100[Formula: see text]mg/kg of geniposide for 7 days by gavage. Lipopolysaccharide (LPS)-induced Bone Marrow Derived Macrophage (BMDM) cell or RAW264.7 cell models were treated with 20, 50 and 100[Formula: see text][Formula: see text]M of geniposide for 4[Formula: see text]h. Myeloperoxidase (MPO) activity and Interleukin-1[Formula: see text] (IL-1[Formula: see text] levels were measured using MPO activity kits and IL-1[Formula: see text] levels enzyme-linked immunosorbent assay (ELISA) kits, respectively. Additionally, Western blot was used to determine the relevant protein expression. As a result, Geniposide could ameliorate inflammatory responses and prevent colitis in DSS-induced acute colitis of mice by activating AMP-activated protein kinase (AMPK)/Transcription 1 (Sirt1) dependent signaling via the suppression of nod-like receptor protein 3 (NLRP3) inflammasome. Geniposide attenuated macrophage differentiation in DSS-induced acute colitis of mice. Geniposide suppressed NLRP3 inflammasome and induced AMPK/Sirt1 signaling in LPS-induced BMDM cell or RAW264.7 cell models. In mechanism studies, the inhibition of AMPK/Sirt1 attenuated the anti-inflammatory effects of geniposide in colitis. The activation of NLRP3 attenuated the anti-inflammatory effects of geniposide in colitis. Taken together, our results demonstrated that geniposide ameliorated inflammatory responses in colitis vai the suppression of NLRP3 inflammasome in macrophages by AMPK/Sirt1-dependent signaling.

Entities:  

Keywords:  AMPK; Colitis; Geniposide; NLRP3; Network Pharmacology; Sirt1

Mesh:

Substances:

Year:  2020        PMID: 33202149     DOI: 10.1142/S0192415X20500846

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  5 in total

1.  Human Umbilical Cord Mesenchymal Stem Cells Improve Premature Ovarian Failure through Cell Apoptosis of miR-100-5p/NOX4/NLRP3.

Authors:  Jing Niu; Fan Yu; Xiping Luo; Shiling Chen
Journal:  Biomed Res Int       Date:  2022-07-07       Impact factor: 3.246

Review 2.  Targeting P2 receptors in purinergic signaling: a new strategy of active ingredients in traditional Chinese herbals for diseases treatment.

Authors:  Xiaopeng Ai; Xing Dong; Ying Guo; Peng Yang; Ya Hou; Jinrong Bai; Sanyin Zhang; Xiaobo Wang
Journal:  Purinergic Signal       Date:  2021-03-22       Impact factor: 3.765

3.  Network pharmacology for systematic understanding of Schisandrin B reduces the epithelial cells injury of colitis through regulating pyroptosis by AMPK/Nrf2/NLRP3 inflammasome.

Authors:  Weiwei Zhang; Wusan Wang; Chaozhuang Shen; Xiaohu Wang; Zhichen Pu; Qin Yin
Journal:  Aging (Albany NY)       Date:  2021-10-09       Impact factor: 5.682

Review 4.  Monoterpenes as Sirtuin-1 Activators: Therapeutic Potential in Aging and Related Diseases.

Authors:  Cátia Sousa; Alexandrina Ferreira Mendes
Journal:  Biomolecules       Date:  2022-06-30

5.  Oridonin attenuates dextran sulfate sodium‑induced ulcerative colitis in mice via the Sirt1/NF‑κB/p53 pathway.

Authors:  Maonan Wang; Bo Xu; Lintao Liu; Dawei Wang
Journal:  Mol Med Rep       Date:  2022-08-25       Impact factor: 3.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.